for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis trial shows drug improves survival for AML patients

The logo of Swiss pharmaceutical company Novartis is seen on its headquarters building in Basel, Switzerland October 27, 2015. REUTERS/Arnd Wiegmann

ZURICH (Reuters) - Novartis’ phase III study for its acute myeloid leukemia (AML) drug showed it improved overall survival by 23 percent for patients with FLT3 mutations, the Swiss drugmaker said on Sunday.

Basel-based Novartis said the study was the first large controlled trial to show overall survival benefit in FLT3-mutated AML, and that worldwide regulatory submissions for midostaurin would begin in 2016.

Reporting by Joshua Franklin; Editing by Kevin Liffey

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up